Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Trial, condition or NCT IDCountrySponsorPhaseStatusConditionReset

182 trials match this view; 341 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 9,058 across 182 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Export filtered registry facts · JSONInteractive world map Germany source-checked report

Recorded study-start years

200411

200711

200811

200922

201222

201311

201433

201533

201611

201733

201833

201944

202055

20211414

20221616

20232323

20242323

20252727

20264444

202744

202911

Current indexed registry status

Recruiting6666

Completed5555

Active, not recruiting2424

Not yet recruiting2020

Withdrawn77

Terminated55

Unknown status33

Suspended11

Enrolling by invitation11

Reported research conditions

Depression1616

Major Depressive Disorder1515

Healthy1212

Treatment Resistant Depression1212

PTSD1010

Anxiety99

Psilocybin88

Opioid Use Disorder88

Psychedelic Experiences77

Alcohol Use Disorder77

Cancer55

Post Traumatic Stress Disorder55

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Matching trial records

182 matching registry records. Dates are registry milestones, not promised results announcements.
Trial	Sponsor and phase	Status	Enrollment	Start / primary completion / completion
Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation NCT07818564 Phase I	Brown University PHASE1	Recruiting Registry updated 2026-10-08	24 ESTIMATED	2026-11 2027-11 2027-11
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease NCT07721467 Alzheimer's Disease	National Institute on Aging (NIA) PHASE2	Recruiting Registry updated 2026-10-08	200 ESTIMATED	2026-10-13 2030-12-31 2030-12-31
A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder NCT07570654 PTSD - Post Traumatic Stress Disorder · PTSD · PTSD Symptoms · PTSD, Post Traumatic Stress Disorder	COMPASS Pathways PHASE2, PHASE3	Recruiting Registry updated 2026-10-06	300 ESTIMATED	2026-09 2028-11 2029-09
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy NCT07227909 Psilocybin · Neuropathy	M.D. Anderson Cancer Center PHASE2	Not yet recruiting Registry updated 2026-10-05	83 ESTIMATED	2026-11-04 2029-01-31 2031-01-31
PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment NCT07610135 Mood (Psychological Function) · Well Being · Mood · Healthy	Johns Hopkins University PHASE1, PHASE2	Recruiting Registry updated 2026-10-01	20 ESTIMATED	2026-10-30 2028-06 2028-12
The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD NCT07332143 PTSD	Emory University PHASE2	Recruiting Registry updated 2026-10-01	150 ESTIMATED	2026-06-08 2027-03 2027-03
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study NCT07360301 Well-Being, Psychological · Psychedelic Experiences	University of Wisconsin, Madison PHASE1	Not yet recruiting Registry updated 2026-09-29	120 ESTIMATED	2026-10 2028-02 2028-02
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease NCT07610369 Depression · Parkinson's Disease (PD)	Yale University PHASE2	Recruiting Registry updated 2026-09-28	40 ESTIMATED	2026-07-10 2030-07 2030-07
Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study NCT07449351 Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI	Yale University EARLY_PHASE1	Not yet recruiting Registry updated 2026-09-24	20 ESTIMATED	2026-10-01 2028-04-01 2028-04-01
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial NCT07296094 Alcohol Use Disorder	Brigham and Women's Hospital PHASE2	Not yet recruiting Registry updated 2026-09-24	36 ESTIMATED	2026-11-15 2029-12-01 2030-02
Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study NCT06988319 Chronic Pelvic Pain	Oregon Health and Science University PHASE1	Recruiting Registry updated 2026-09-23	15 ESTIMATED	2026-11-01 2027-12-31 2027-12-31
ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted Therapy NCT07833761 Borderline Personality Disorder · Borderline Personality Pathology · Depressive Symptoms · Emotion Dysregulation · Suicidal Ideation	University of Minnesota PHASE1	Not yet recruiting Registry updated 2026-09-22	18 ESTIMATED	2026-12-01 2029-12-31 2030-12-31
Psilocybin in the Treatment of Methamphetamine Use Disorder NCT07774702 Methamphetamine Use Disorder	Peter Hendricks PHASE2	Not yet recruiting Registry updated 2026-09-21	42 ESTIMATED	2027-02-01 2032-02-01 2032-02-01
A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults NCT07516405 Healthy Volunteer · Older Adults (65-85 Years)	University of Colorado, Denver PHASE1	Recruiting Registry updated 2026-09-16	40 ESTIMATED	2026-04-01 2028-03 2028-03
PRoMiSS: Psilocybin and the Role of Music in Set and Setting NCT07180108 Psilocybin · Music Intervention	Johns Hopkins University PHASE1	Recruiting Registry updated 2026-09-15	100 ESTIMATED	2025-08-12 2028-06 2028-08
Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia NCT07607938 Anhedonia · Emotional Blunting	NYU Langone Health PHASE1	Recruiting Registry updated 2026-09-15	90 ESTIMATED	2026-09 2030-08-01 2030-09-30
Psilocybin Administration With 5-HT1a Blockade NCT07565493 Psychedelic Effects in Healthy Volunteers	Johns Hopkins University EARLY_PHASE1	Recruiting Registry updated 2026-09-14	18 ESTIMATED	2026-08-12 2028-06-15 2028-06-15
TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy NCT06200155 Depression, Anxiety · Psilocybin-Assisted Psychotherapy · Advanced Cancer	M.D. Anderson Cancer Center PHASE2	Recruiting Registry updated 2026-09-11	48 ESTIMATED	2024-04-16 2026-12-31 2026-12-31
A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease NCT07386730 Anhedonia in Healthy Volunteers · Older Adults (50-90 Years)	Jennifer Mitchell PHASE1	Recruiting Registry updated 2026-09-09	80 ESTIMATED	2026-06-01 2030-02 2030-02
Effects of Psilocybin in Obsessive Compulsive Disorder NCT05546658 Obsessive-Compulsive Disorder	Johns Hopkins University EARLY_PHASE1	Active, not recruiting Registry updated 2026-09-04	35 ACTUAL	2022-11-28 2026-12-30 2027-09-12
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease NCT04123314 Depressive Symptoms · Depression · Alzheimer Disease · Mild Cognitive Impairment	Johns Hopkins University EARLY_PHASE1	Recruiting Registry updated 2026-09-04	20 ESTIMATED	2021-03-24 2027-06-30 2027-09-30
Psilocybin and Affective Function in Chronic Lower Back Pain Depression NCT06355414 Chronic Low-back Pain · Depression	Johns Hopkins University PHASE1	Recruiting Registry updated 2026-09-04	40 ESTIMATED	2024-04-22 2026-12-30 2026-12-30
Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD) NCT06989957 Posttraumatic Stress Disorder	Johns Hopkins University PHASE1	Recruiting Registry updated 2026-09-04	40 ESTIMATED	2025-09-17 2028-08 2029-08
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission NCT06430541 Breast Cancer · Ovarian Cancer	University of Colorado, Denver PHASE1	Recruiting Registry updated 2026-09-04	20 ESTIMATED	2024-11-21 2026-12 2028-12
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study NCT04932434 Parkinson Disease · Depression · Anxiety	Joshua Woolley, MD, PhD PHASE2	Completed Registry updated 2026-09-03	12 ACTUAL	2021-08-15 2024-12-31 2024-12-31
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder NCT06349083 Alcohol Use Disorder	NYU Langone Health PHASE2	Recruiting Registry updated 2026-09-02	200 ESTIMATED	2026-09-01 2030-05 2030-05
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)] NCT06814522 Burnout · Burnout, Healthcare Workers	University of California, San Diego PHASE1, PHASE2	Recruiting Registry updated 2026-09-02	30 ESTIMATED	2025-01-13 2028-06 2028-08
Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes NCT07306364 Chronic Low Back Pain (CLBP) · Physical Therapy · Psilocybin	Yale University PHASE2	Not yet recruiting Registry updated 2026-08-19	45 ESTIMATED	2026-10 2029-06 2029-06
An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers NCT05220046 Pancreas Cancer · Biliary Tract Cancer · Psychological Distress · Gastrointestinal Cancer	University of Nebraska PHASE1	Completed Registry updated 2026-08-19	18 ACTUAL	2023-04-10 2025-11-17 2025-11-17
An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life NCT07719088 Aging · Longevity · Biomarkers of Aging	Charles Raison PHASE1	Not yet recruiting Registry updated 2026-08-17	50 ESTIMATED	2026-12 2028-04 2028-12
Safety for Home Administration of Microdose Psilocybin Use NCT06450210 Psychedelic Experiences	Johns Hopkins University PHASE1	Completed Registry updated 2026-08-14	17 ACTUAL	2024-12-06 2026-07-31 2026-07-31
A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans NCT07226232 Major Depression	VA Office of Research and Development PHASE3	Recruiting Registry updated 2026-08-14	240 ESTIMATED	2026-08-03 2030-12-02 2031-06-30
Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study) NCT06692192 Psilocybin	University of Wisconsin, Madison PHASE1	Recruiting Registry updated 2026-08-13	60 ESTIMATED	2025-08-07 2027-12 2027-12
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy NCT06899165 Psychological Stress · Depression · Anxiety	Rachel Yehuda PHASE2	Recruiting Registry updated 2026-08-13	100 ESTIMATED	2026-08-28 2029-05-31 2030-01-02
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder NCT06247839 Major Depressive Disorder	Sharmin Ghaznavi PHASE3	Recruiting Registry updated 2026-08-13	20 ESTIMATED	2024-09-10 2028-06-30 2028-06-30
PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD) NCT06853912 Alcohol Use Disorder (AUD) · PTSD	Nathan Brashares Sackett PHASE2	Active, not recruiting Registry updated 2026-08-13	40 ESTIMATED	2025-06-01 2026-11-01 2027-06-01
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors NCT06801041 Depression · Anxiety · Cancer	M.D. Anderson Cancer Center PHASE2	Recruiting Registry updated 2026-08-12	20 ESTIMATED	2025-05-23 2027-03-31 2029-03-31
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality NCT06706232 Bipolar II Disorder · Depression, Bipolar · Suicidality	The University of Texas Health Science Center, Houston PHASE2	Recruiting Registry updated 2026-08-12	10 ESTIMATED	2025-07-07 2027-08 2027-08
Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids NCT06827054 Hematopoietic and Lymphatic System Neoplasm · Malignant Solid Neoplasm	Roswell Park Cancer Institute PHASE2	Not yet recruiting Registry updated 2026-08-12	20 ESTIMATED	2026-09-15 2027-05-05 2027-05-05
Psilocybin Recovery Intervention for Stopping Methamphetamine Use NCT07756736 Methamphetamine Use Disorder · Human Immunodeficiency Virus (HIV)	Nicky Mehtani, MD, MPH PHASE2	Not yet recruiting Registry updated 2026-08-11	30 ESTIMATED	2026-11 2029-04 2029-06
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis NCT06656702 Amyotrophic Lateral Sclerosis	Johns Hopkins University EARLY_PHASE1	Recruiting Registry updated 2026-08-11	24 ESTIMATED	2025-04-09 2027-01-30 2027-07-01
An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study) NCT06512194 Depression	Charles Raison PHASE2	Recruiting Registry updated 2026-08-10	141 ESTIMATED	2025-05-13 2029-05 2029-05
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression NCT05711940 Treatment Resistant Depression	COMPASS Pathways PHASE3	Active, not recruiting Registry updated 2026-08-10	572 ACTUAL	2023-02-14 2025-11-13 2026-12
Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury NCT07251491 Spinal Cord Injury · Depression - Major Depressive Disorder · Veteran	James J. Peters Veterans Affairs Medical Center PHASE1, PHASE2	Recruiting Registry updated 2026-08-10	30 ESTIMATED	2026-08-06 2028-03-01 2028-03-01
A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression NCT05624268 Treatment Resistant Depression	COMPASS Pathways PHASE3	Completed Registry updated 2026-08-10	258 ACTUAL	2023-01-24 2025-05-28 2026-04-15
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease NCT06455293 Parkinson Disease · Depression	Joshua Woolley, MD, PhD PHASE2	Recruiting Registry updated 2026-08-07	60 ESTIMATED	2024-08-19 2027-06 2028-06
Open Label Psilocybin Brain Stimulation and Imaging Pilot Study NCT06835699 Healthy Volunteers	Johns Hopkins University PHASE1	Completed Registry updated 2026-08-07	10 ACTUAL	2025-04-18 2026-05-21 2026-05-21
Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder NCT07406828 Pain Management · Postoperative Pain	Trent Emerick PHASE1	Not yet recruiting Registry updated 2026-08-06	70 ESTIMATED	2027-12-31 2029-04 2029-08
An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy NCT06233344 Mental Health	University of Southern California PHASE2	Recruiting Registry updated 2026-08-06	40 ESTIMATED	2025-07-30 2027-08 2028-08
Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer NCT06001749 Opioid-Related Disorders · Pain Management · Pain Management and Care · Advanced Cancer · Advanced Cancers	Yvan Beaussant, MD, MSci PHASE2	Recruiting Registry updated 2026-08-05	15 ESTIMATED	2024-09-23 2026-10-01 2026-12-31
Psilocybin as a Treatment for Chronic Pain in Smokers NCT07118332 Smokers With Chronic Pain	Yale University EARLY_PHASE1	Recruiting Registry updated 2026-08-03	10 ESTIMATED	2026-07-06 2027-10-01 2027-12-01
A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression NCT07336238 Anxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm	University of Washington PHASE2	Active, not recruiting Registry updated 2026-07-31	18 ESTIMATED	2026-05-19 2026-12-01 2027-05-01
An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD NCT07275970 PTSD	Scottsdale Research Institute PHASE1	Active, not recruiting Registry updated 2026-07-29	24 ESTIMATED	2026-03-20 2026-07-30 2026-10-01
Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin NCT05866471 Healthy · Psychedelic Experiences · Vagus Nerve Stimulation	University of Wisconsin, Madison PHASE1	Recruiting Registry updated 2026-07-29	108 ESTIMATED	2025-01-27 2027-11 2028-01
A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. NCT07347405 Obsessive-Compulsive Disorder	Francisco A Moreno PHASE1	Recruiting Registry updated 2026-07-23	30 ESTIMATED	2026-05-18 2028-12-31 2029-01-31
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought NCT05301608 Healthy	Johns Hopkins University PHASE1, PHASE2	Recruiting Registry updated 2026-07-23	30 ESTIMATED	2022-03-03 2026-12-01 2027-01-01
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD) NCT06308653 Depressive Disorder, Major	Usona Institute PHASE3	Active, not recruiting Registry updated 2026-07-23	238 ACTUAL	2024-03-13 2026-01-05 2027-01-30
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety NCT06820723 Depression · Anxiety · Major Depressive Disorder	Ohio State University PHASE2	Recruiting Registry updated 2026-07-23	40 ESTIMATED	2026-08-01 2028-09 2028-11
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial NCT06067737 Opioid Use Disorder	Johns Hopkins University PHASE2	Recruiting Registry updated 2026-07-17	90 ESTIMATED	2024-02-08 2028-07 2029-05
Mechanistic Studies of Psilocybin in Headache Disorders NCT06464367 Migraine	Yale University EARLY_PHASE1	Recruiting Registry updated 2026-07-13	50 ESTIMATED	2025-05-19 2027-12-31 2027-12-31
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain NCT05265546 Perception Disorders	University of California, Berkeley PHASE1	Recruiting Registry updated 2026-07-10	80 ESTIMATED	2024-03-08 2028-12-31 2028-12-31
The Effects of Psilocybin on Social Connectedness NCT07693153 Loneliness · Grief	Yale University PHASE1	Not yet recruiting Registry updated 2026-07-09	51 ESTIMATED	2026-08-31 2031-12-15 2031-12-15
Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects NCT06624137 OCD · Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD) · Healthy Volunteer · Migraine · PTSD · PTSD - Post Traumatic Stress Disorder · Addiction · Tobacco Use Disorder · Obsessive Compulsive Disorder (OCD) · Opioid Use Disorder	Yale University Phase not reported	Terminated Registry updated 2026-07-09	5 ACTUAL	2024-12-12 2026-06-14 2026-06-14
Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder NCT06810310 Opioid Use Disorder	University of Pennsylvania PHASE2	Recruiting Registry updated 2026-07-09	24 ESTIMATED	2025-12-22 2027-05-01 2027-05-01
Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation NCT04161066 Opioid Use Disorder	University of Wisconsin, Madison PHASE1	Recruiting Registry updated 2026-07-07	10 ESTIMATED	2021-01-13 2026-12 2026-12
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) NCT06160284 Opioid Use Disorder	Yale University PHASE1	Recruiting Registry updated 2026-07-07	12 ESTIMATED	2025-05-28 2027-01 2027-01
A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD) NCT06902974 Post Traumatic Stress Disorder · PTSD	Sunstone Medical PHASE2	Recruiting Registry updated 2026-07-01	70 ESTIMATED	2026-05-23 2027-11 2028-05
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder NCT05452772 Tobacco Use Disorder	Johns Hopkins University PHASE2	Recruiting Registry updated 2026-06-29	66 ESTIMATED	2023-11-01 2026-12 2027-05
A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD) NCT07104916 Post Traumatic Stress Disorder · Depression - Major Depressive Disorder	Anthony P King PHASE2	Recruiting Registry updated 2026-06-25	30 ESTIMATED	2026-07-01 2029-09 2029-12
Psilocybin-Assisted Therapy for Prolonged Grief NCT06724289 Prolonged Grief Disorder	University of Virginia EARLY_PHASE1	Recruiting Registry updated 2026-06-23	12 ESTIMATED	2026-03-24 2027-08 2027-08
Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy NCT06407635 Post Traumatic Stress Disorder	Johns Hopkins University PHASE1	Active, not recruiting Registry updated 2026-06-22	20 ESTIMATED	2024-06-07 2026-03-09 2027-05
The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function NCT07079852 Healthy	Manoj Doss PHASE1, PHASE2	Not yet recruiting Registry updated 2026-06-15	48 ESTIMATED	2026-09 2028-08 2028-08
Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling NCT05698511 Psychedelic Experiences · Neuroimaging · Healthy Volunteers	Robin Carhart-Harris, PhD, MA PHASE1	Active, not recruiting Registry updated 2026-06-05	12 ESTIMATED	2023-07-31 2026-01-30 2027-01-30
Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study NCT05370911 Obsessive-Compulsive Disorder	Yale University PHASE1	Active, not recruiting Registry updated 2026-06-04	28 ACTUAL	2023-07-20 2026-02-17 2027-02
2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers NCT06626139 Healthy Participants With Lower-than-average Mental Well-being	Robin Carhart-Harris, PhD, MA PHASE2	Recruiting Registry updated 2026-06-04	120 ESTIMATED	2024-10-20 2027-11-30 2028-11-30
Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial NCT06230757 Major Depressive Disorder · Anhedonia · Treatment Resistant Depression	University of Colorado, Denver PHASE2	Completed Registry updated 2026-05-22	20 ACTUAL	2024-07-08 2026-05-08 2026-05-08
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder NCT07506395 PTSD	University of New Mexico PHASE1	Recruiting Registry updated 2026-05-22	36 ESTIMATED	2026-05-01 2027-05-01 2028-05-01
A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression NCT07582120 Depression	Washington University School of Medicine PHASE2	Not yet recruiting Registry updated 2026-05-20	50 ESTIMATED	2026-06 2031-06 2031-12
Psilocybin-assisted Cognitive Behavioral Therapy for Depression NCT05227612 Major Depressive Disorder	University of California, Los Angeles PHASE1	Completed Registry updated 2026-05-19	16 ACTUAL	2023-06-27 2025-09-12 2025-09-12
Psilocybin-facilitated Treatment for Cocaine Use NCT02037126 Cocaine-Related Disorders	University of Alabama at Birmingham PHASE2	Completed Registry updated 2026-05-18	40 ACTUAL	2015-05 2024-05 2024-05
Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY) NCT07216404 Lung Non-Small Cell Carcinoma · Unipolar Depression	Alan Davis PHASE2	Recruiting Registry updated 2026-05-14	10 ESTIMATED	2026-01-01 2027-10-31 2027-10-31
Psilocybin for Treatment of Obsessive Compulsive Disorder NCT06992999 Obsessive - Compulsive Disorder	Francisco A Moreno PHASE1, PHASE2	Not yet recruiting Registry updated 2026-05-12	20 ESTIMATED	2026-09-08 2028-12 2028-12
Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample NCT05322954 Methamphetamine Use Disorder · Substance-Related Disorders · Chemically-Induced Disorders · Substance Use Disorders · Stimulant-Use Disorder	University of Wisconsin, Madison PHASE1	Terminated Registry updated 2026-05-12	5 ACTUAL	2023-03-03 2024-03-07 2024-03-07
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer NCT05947383 Cancer · Major Depressive Disorder	Sunstone Medical PHASE2	Active, not recruiting Registry updated 2026-05-06	56 ESTIMATED	2023-10-23 2027-04-30 2027-11-01
Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study NCT06303739 Refractory Depression · Treatment Resistant Depression	University of North Carolina, Chapel Hill PHASE3	Active, not recruiting Registry updated 2026-05-06	20 ACTUAL	2024-04-19 2026-04-09 2027-03-26
A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder NCT07479550 Major Depression	Stanford University PHASE2	Not yet recruiting Registry updated 2026-05-06	10 ESTIMATED	2026-07 2027-07 2027-08
A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control NCT04353921 Major Depressive Disorder	Usona Institute Phase not reported	Terminated Registry updated 2026-05-04	26 ACTUAL	2020-06-30 2022-10-18 2022-10-18
Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder NCT07566104 Depression - Major Depressive Disorder · Psilocybin · Cognitive Behavioral Therapy	University of California, Los Angeles PHASE2	Not yet recruiting Registry updated 2026-05-04	30 ESTIMATED	2027-01 2028-12 2028-12
A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain NCT05351541 Chronic Low-back Pain	Joshua Woolley, MD, PhD PHASE1, PHASE2	Active, not recruiting Registry updated 2026-04-29	30 ESTIMATED	2023-12-01 2026-07 2026-09
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder NCT04982796 Amphetamine-Related Disorders	Portland VA Research Foundation, Inc PHASE1, PHASE2	Active, not recruiting Registry updated 2026-04-22	30 ESTIMATED	2022-07-07 2026-12-31 2026-12-31
A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD) NCT03866174 Depressive Disorder, Major	Usona Institute PHASE2	Completed Registry updated 2026-04-22	347 ACTUAL	2020-01-23 2022-06-28 2022-06-28
Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder NCT06102434 Cocaine Use Disorder	University of California, Los Angeles EARLY_PHASE1	Suspended Registry updated 2026-04-07	10 ESTIMATED	2029-02-01 2029-05 2029-06
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder NCT07499583 Treatment Resistant Depression · Substance Use Disorders	Indiana University PHASE1, PHASE2	Not yet recruiting Registry updated 2026-03-30	50 ESTIMATED	2026-08-01 2031-01-01 2031-02-28
Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder NCT06660381 Cannabis Use Disorder	Johns Hopkins University PHASE1	Recruiting Registry updated 2026-03-18	12 ESTIMATED	2024-11-08 2026-11 2026-12
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder NCT04620759 Major Depressive Disorder · Alcohol Use Disorder	Johns Hopkins University PHASE2	Active, not recruiting Registry updated 2026-03-13	90 ESTIMATED	2021-04-14 2026-03-02 2027-03-30
Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health NCT05227742 Demoralization	University of Alabama at Birmingham EARLY_PHASE1	Withdrawn Registry updated 2026-03-11	0 ACTUAL	2023-08-15 2026-03 2026-03
Psilocybin-facilitated Treatment for Chronic Pain NCT05068791 Fibromyalgia, Primary	University of Alabama at Birmingham EARLY_PHASE1	Recruiting Registry updated 2026-03-11	30 ESTIMATED	2023-11-01 2026-12-31 2026-12-31
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study NCT06442423 Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms · PTSD · Substance Use · Substance Use Disorder (SUD) · OCD	Yale University PHASE1	Recruiting Registry updated 2026-03-11	50 ESTIMATED	2024-10-17 2027-12 2027-12
Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome. NCT06760533 IBS - Irritable Bowel Syndrome	NYU Langone Health EARLY_PHASE1	Not yet recruiting Registry updated 2026-03-05	10 ESTIMATED	2026-08 2026-12 2026-12
Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial NCT05554094 PTSD · Stress Disorders, Traumatic · Stress Disorders, Post-Traumatic · Trauma and Stressor Related Disorders · Mental Disorder	Ohio State University PHASE2	Active, not recruiting Registry updated 2026-03-04	15 ESTIMATED	2023-01-01 2025-12-31 2026-07-31
Study of Psilocybin for Anorexia in Young Adults NCT06399263 Anorexia Nervosa	Marissa Raymond-Flesch, MD, MPH PHASE2	Recruiting Registry updated 2026-03-03	40 ESTIMATED	2024-11-18 2029-11 2029-11
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial NCT06005662 Opioid Use Disorder	Johns Hopkins University PHASE2	Withdrawn Registry updated 2026-02-23	0 ACTUAL	2027-04 2028-07 2028-07
Investigation of Psychedelic Effects in Psychoactive Substances NCT06772753 Psychedelic Effects in Healthy Volunteers	Johns Hopkins University PHASE1	Recruiting Registry updated 2026-02-23	50 ESTIMATED	2025-02-05 2027-06 2027-12
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study NCT04950608 Hospice · Psilocybin · Demoralization · Terminal Illness · Cancer-related Problem/Condition · Psychotherapy · Terminal Cancer · Cancer Terminal	Yvan Beaussant, MD, MSci PHASE2	Completed Registry updated 2026-02-17	15 ACTUAL	2022-03-09 2024-07-27 2025-12-31
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability NCT07053917 Stroke · Chronic Stroke · Intracerebral Haemorrhage · Intracerebral Haemorrhage (ICH) · Intracerebral Hemorrhage Basal Ganglia · Ischemic Stroke · Ischemic Stroke and Hemorrhagic Stroke · Hemiparesis After Stroke · Hemiplegia Following Ischemic Stroke · Hemiplegia and Hemiparesis · Hemiplegia and/or Hemiparesis Following Stroke · Middle Cerebral Artery Stroke	Johns Hopkins University PHASE1	Recruiting Registry updated 2026-02-13	20 ESTIMATED	2026-02-09 2027-02 2027-03
Psilocybin-Assisted Cognitive Behavioral Therapy for Depression NCT07281352 Major Depressive Diorder	University of California, Los Angeles PHASE1, PHASE2	Recruiting Registry updated 2026-02-12	50 ESTIMATED	2026-01-05 2027-11-30 2027-11-30
A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design NCT06206265 Irritable Bowel Syndrome	TRYP Therapeutics PHASE2	Active, not recruiting Registry updated 2026-02-05	14 ACTUAL	2024-01-17 2026-03-01 2026-03-01
A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment NCT06796062 Opioid Use Disorder	NYU Langone Health PHASE2	Recruiting Registry updated 2026-01-23	480 ESTIMATED	2025-12-17 2029-02 2029-02
The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma NCT06888128 PTSD	Baylor College of Medicine PHASE2	Recruiting Registry updated 2026-01-22	15 ESTIMATED	2025-01-30 2026-12-15 2026-12-15
Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain NCT05224336 Phantom Limb Pain	University of California, San Diego PHASE1	Completed Registry updated 2026-01-09	10 ACTUAL	2022-10-03 2024-03-07 2024-03-07
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation NCT05220410 Treatment Resistant Depression · Suicidal Ideation	Sheppard Pratt Health System PHASE2	Completed Registry updated 2025-12-24	20 ACTUAL	2022-03-28 2025-05-12 2025-05-12
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder NCT05399498 Borderline Personality Disorder · Major Depressive Disorder	University of Chicago PHASE2	Completed Registry updated 2025-12-23	9 ACTUAL	2023-11-01 2025-12-01 2025-12-01
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter NCT07296328 Stuttering	NYU Langone Health PHASE2	Not yet recruiting Registry updated 2025-12-22	25 ESTIMATED	2026-01-15 2027-04-01 2027-04-01
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer NCT05398484 Advanced Cancer	NYU Langone Health PHASE2, PHASE3	Recruiting Registry updated 2025-12-04	200 ESTIMATED	2023-05-24 2027-01-01 2027-01-01
Psilocybin vs Ketamine for Alcohol Use Disorder NCT06405607 Alcohol Use Disorder · Alcohol Dependence · Alcohol Abuse	University of Iowa PHASE2	Recruiting Registry updated 2025-11-28	80 ESTIMATED	2025-06-12 2028-04 2028-04
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder NCT06132178 Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression · Depression	University of Texas at Austin PHASE2	Recruiting Registry updated 2025-11-26	100 ESTIMATED	2025-01-10 2029-12-31 2030-12-31
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life NCT05403086 Demoralization	Charles S. Grob, M.D. PHASE2	Recruiting Registry updated 2025-11-25	100 ESTIMATED	2025-01-19 2026-12-31 2027-12-31
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder NCT05421065 Alcohol Use Disorder	Peggy C Nopoulos PHASE2	Active, not recruiting Registry updated 2025-11-17	20 ESTIMATED	2024-02-02 2025-08-30 2026-09
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder NCT03554174 Major Depressive Disorder	Yale University PHASE1	Active, not recruiting Registry updated 2025-11-05	18 ESTIMATED	2018-02-27 2021-07-08 2026-09
A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer NCT05847686 Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm	University of Washington PHASE1, PHASE2	Completed Registry updated 2025-11-05	55 ACTUAL	2023-06-27 2024-04-08 2024-10-17
Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin NCT04501653 Psilocybin	Washington University School of Medicine EARLY_PHASE1	Completed Registry updated 2025-10-31	11 ACTUAL	2021-06-01 2023-03-19 2023-03-19
A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)? NCT06786325 Opioid Use Disorder	Anna Rose Childress, Ph.D. PHASE2	Recruiting Registry updated 2025-10-29	36 ESTIMATED	2025-10-07 2027-06 2027-10
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults NCT06367738 Aging	University of California, Berkeley PHASE1	Recruiting Registry updated 2025-10-21	40 ESTIMATED	2025-11 2026-12-30 2027-12-30
A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer NCT06644170 Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm	University of Washington PHASE1	Completed Registry updated 2025-10-14	15 ACTUAL	2024-11-19 2025-09-30 2025-09-30
A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine NCT06899594 Methamphetamine Use Disorder	Kevin Murnane EARLY_PHASE1	Recruiting Registry updated 2025-10-07	20 ESTIMATED	2025-04-04 2027-03 2027-03
Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism NCT07189988 Alcohol Use Disorder	Healing Advocacy Fund Phase not reported	Active, not recruiting Registry updated 2025-09-24	20 ACTUAL	2025-03-05 2026-06-10 2026-08-05
Effects of Psilocybin in Post-Treatment Lyme Disease NCT05305105 Post-Treatment Lyme Disease · Chronic Lyme Disease · Lyme Disease, Chronic	Johns Hopkins University PHASE1	Completed Registry updated 2025-08-20	20 ACTUAL	2022-07-01 2024-10-26 2025-04-07
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder NCT05733546 Major Depressive Disorder	COMPASS Pathways PHASE2	Active, not recruiting Registry updated 2025-08-19	102 ACTUAL	2023-01-30 2025-09 2025-09
The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC) NCT05506982 Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm	Emory University PHASE1	Completed Registry updated 2025-07-23	11 ACTUAL	2022-11-01 2024-04-25 2025-01-24
Visual Surround Suppression and Perceptual Expectation Under Psilocybin NCT04424225 Perception Disturbance · Visual Suppression · Psychedelic Experiences	University of Minnesota PHASE1	Terminated Registry updated 2025-06-27	10 ACTUAL	2021-08-30 2023-09-01 2023-09-01
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder NCT05312151 Post Traumatic Stress Disorder	COMPASS Pathways PHASE2	Completed Registry updated 2025-06-13	22 ACTUAL	2022-06-10 2024-02-12 2024-02-12
Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults NCT05317689 Healthy	University of California, San Francisco PHASE1	Active, not recruiting Registry updated 2025-06-10	20 ESTIMATED	2022-05-26 2025-01-16 2025-07
Psilocybin With Intracranial Neural Sensing NCT06919640 Chronic Pain	Joshua Woolley, MD, PhD PHASE1	Enrolling by invitation Registry updated 2025-06-06	20 ESTIMATED	2025-06-01 2028-04-30 2028-04-30
Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study NCT06372197 Depression	Matthew Hicks NA	Completed Registry updated 2025-06-05	20 ACTUAL	2024-08-01 2025-05-14 2025-05-14
Optimizing Microdosing and Meditation NCT06560658 Meditation · Microdosing	National University of Natural Medicine NA	Withdrawn Registry updated 2025-06-05	0 ACTUAL	2024-10-01 2025-10-01 2025-11-01
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study NCT01943994 Nicotine Dependence	Johns Hopkins University NA	Completed Registry updated 2025-05-25	82 ACTUAL	2008-09 2023-05-01 2023-11-14
Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase NCT05592379 Healthy · Psychedelic Experiences · Sleep	University of Wisconsin, Madison PHASE1	Completed Registry updated 2025-05-16	6 ACTUAL	2023-11-07 2025-02-19 2025-02-19
Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder NCT06592833 Major Depressive Disorder	Icahn School of Medicine at Mount Sinai PHASE2	Recruiting Registry updated 2025-05-14	60 ESTIMATED	2025-02-25 2028-03-01 2028-03-01
A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia NCT05128162 Fibromyalgia	Kevin Boehnke PHASE2	Completed Registry updated 2025-04-16	17 ACTUAL	2023-09-27 2024-06-12 2024-06-12
A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout NCT05163496 Burnout, Caregiver · Burnout, Professional · COVID-19 · Depression · Post Traumatic Stress Disorder · Moral Injury	University of Washington PHASE3	Completed Registry updated 2025-03-18	30 ACTUAL	2022-03-03 2023-12-30 2024-06-30
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety NCT00302744 Anxiety	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center PHASE1, PHASE2	Completed Registry updated 2025-03-13	12 ACTUAL	2004-04 2008-12 2008-12
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study NCT05481736 Anorexia Nervosa	COMPASS Pathways PHASE2	Completed Registry updated 2024-12-04	32 ACTUAL	2022-10-12 2024-11-18 2024-11-18
Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates. NCT03356483 Obsessive-Compulsive Disorder	Yale University PHASE1	Completed Registry updated 2024-11-20	31 ACTUAL	2018-11-13 2024-07-25 2024-07-25
A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder NCT05035927 Binge Eating Disorder	TRYP Therapeutics PHASE2	Completed Registry updated 2024-11-19	5 ACTUAL	2022-03-16 2024-03-07 2024-06-07
PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout NCT05557643 Depression · Burnout, Professional	University of Utah PHASE1	Completed Registry updated 2024-11-12	24 ACTUAL	2023-01-02 2024-09-20 2024-09-20
An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder NCT05065294 Bipolar II Disorder	University of California, San Francisco PHASE2	Active, not recruiting Registry updated 2024-09-25	14 ESTIMATED	2022-01-28 2024-08-01 2025-07
Psilocybin for Treatment of Obsessive Compulsive Disorder NCT03300947 Obsessive-compulsive Disorder (OCD)	University of Arizona PHASE1	Completed Registry updated 2024-08-30	15 ACTUAL	2019-01-02 2023-10-30 2023-12-30
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) NCT04433858 Treatment Resistant Depression	Sheppard Pratt Health System PHASE2	Active, not recruiting Registry updated 2024-08-09	27 ACTUAL	2021-03-01 2025-06-01 2026-05-01
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion NCT02243813 Healthy	Johns Hopkins University PHASE1	Completed Registry updated 2024-06-18	24 ACTUAL	2015-03 2024-05-31 2024-05-31
A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer NCT04522804 Cancer	University of Utah EARLY_PHASE1	Completed Registry updated 2024-03-20	12 ACTUAL	2021-10-04 2022-06-11 2022-12-16
Repeat Dosing of Psilocybin in Headache Disorders NCT04218539 Migraine Headache	Yale University PHASE1	Completed Registry updated 2024-02-09	18 ACTUAL	2021-08-10 2023-11-05 2023-11-05
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD NCT05381974 Treatment-Resistant Major Depressive Disorder	Massachusetts General Hospital PHASE2	Withdrawn Registry updated 2024-01-24	0 ACTUAL	2022-09-15 2023-06-01 2023-06-01
Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma. NCT00979693 Anxiety · Stage IV Melanoma	Multidisciplinary Association for Psychedelic Studies PHASE2	Withdrawn Registry updated 2023-12-26	0 ACTUAL	2012-01 2013-04 2013-06
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders NCT02981173 Cluster Headache	Yale University PHASE1	Completed Registry updated 2023-12-15	25 ACTUAL	2016-12-05 2022-06-30 2022-10-21
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression NCT04739865 Treatment Resistant Depression	COMPASS Pathways PHASE2	Completed Registry updated 2023-11-09	19 ACTUAL	2020-08-10 2021-10-14 2021-10-14
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II NCT03806985 Post-Traumatic Headache	Yale University PHASE1	Terminated Registry updated 2023-10-12	12 ACTUAL	2019-03-28 2023-06-27 2023-06-27
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I NCT03341689 Migraine Headache	Yale University PHASE1	Completed Registry updated 2023-10-12	14 ACTUAL	2017-11-01 2021-04-30 2021-10-31
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence NCT01534494 Alcohol Dependence	University of New Mexico PHASE2	Completed Registry updated 2023-09-26	10 ACTUAL	2012-01 2013-09 2014-03
A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics NCT05478278 QTc Interval · Pharmacokinetics	Usona Institute PHASE1	Completed Registry updated 2023-08-15	60 ACTUAL	2022-06-22 2023-08-09 2023-08-09
Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers NCT04842045 Psychedelic Experiences · Amnesia	University of Wisconsin, Madison PHASE1	Completed Registry updated 2023-05-19	8 ACTUAL	2021-05-21 2022-11-17 2022-11-17
A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin NCT05467761 Healthy	University of Wisconsin, Madison PHASE1	Withdrawn Registry updated 2023-05-15	0 ACTUAL	2023-06 2024-03 2024-03
Effects of Psilocybin in Anorexia Nervosa NCT04052568 Anorexia Nervosa	Johns Hopkins University PHASE1	Completed Registry updated 2023-05-06	22 ACTUAL	2019-08-26 2022-01-05 2023-04-20
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression NCT03775200 Treatment Resistant Depression	COMPASS Pathways PHASE2	Completed Registry updated 2023-04-24	233 ACTUAL	2019-03-01 2021-07-30 2021-09-27
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder NCT04656301 Body Dysmorphic Disorders	New York State Psychiatric Institute PHASE2	Completed Registry updated 2023-03-13	12 ACTUAL	2021-02-26 2022-11-02 2022-11-02
SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression NCT05601648 Major Depressive Disorder · Anhedonia	Washington University School of Medicine PHASE2	Withdrawn Registry updated 2023-01-30	0 ACTUAL	2023-07-01 2025-01-01 2025-07-01
Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder NCT04410913 Alcohol Use Disorder	Keith Heinzerling PHASE2	Active, not recruiting Registry updated 2023-01-17	20 ACTUAL	2021-02-18 2023-02 2023-02
NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System. NCT05042466 Trauma, Nervous System	NWTraumatherapies PHASE1	Unknown status Registry updated 2022-11-16	30 ESTIMATED	2023-09-03 2025-08-30 2025-10-03
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence NCT02061293 Alcohol Dependence	NYU Langone Health PHASE2	Completed Registry updated 2022-11-08	95 ACTUAL	2014-06 2021-07-30 2021-07-30
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. NCT04433845 Treatment Resistant Depression	Sheppard Pratt Health System PHASE2	Unknown status Registry updated 2022-10-25	15 ACTUAL	2021-03-01 2023-01-15 2023-04-15
Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU) NCT04519957 Treatment Resistant Depression	COMPASS Pathways Phase not reported	Completed Registry updated 2022-09-22	66 ACTUAL	2020-07-20 2022-08-11 2022-08-11
Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy NCT04661514 Anorexia Nervosa	University of California, San Diego PHASE2	Completed Registry updated 2022-07-25	16 ACTUAL	2021-05-01 2022-03-10 2022-06-10
A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion NCT02421263 Religious or Spiritual Problem	NYU Langone Health PHASE1	Completed Registry updated 2022-02-14	12 ACTUAL	2015-04 2020-06-05 2020-06-05
Effects of Psilocybin in Major Depressive Disorder NCT03181529 Major Depressive Disorder	Johns Hopkins University PHASE2	Completed Registry updated 2021-12-15	27 ACTUAL	2017-08-10 2020-12-02 2020-12-02
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder NCT04593563 Major Depressive Disorder	Maryland Oncology Hematology, PA PHASE2	Unknown status Registry updated 2021-10-15	30 ACTUAL	2020-09-01 2022-10 2023-10
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors NCT02950467 Distress · Depression · Grief	Joshua Woolley PHASE1	Completed Registry updated 2021-01-07	30 ACTUAL	2018-01-05 2019-12-31 2019-12-31
Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients NCT00957359 Cancer	NYU Langone Health EARLY_PHASE1	Completed Registry updated 2020-10-20	29 ACTUAL	2009-02 2018-09-06 2018-09-06
Pharmacokinetics of Psilocybin in Normal Adult Volunteers NCT02163707 Healthy	University of Wisconsin, Madison PHASE1	Completed Registry updated 2020-04-15	12 ACTUAL	2014-06 2015-12 2015-12
Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators NCT02145091 Healthy	Johns Hopkins University PHASE1	Completed Registry updated 2019-12-30	40 ACTUAL	2014-05 2019-12-26 2019-12-26
Measurement of Persisting Changes in Emotional Brain Functioning Produced by Psilocybin NCT02971605 Healthy	Johns Hopkins University PHASE1, PHASE2	Completed Registry updated 2019-09-10	13 ACTUAL	2017-07-01 2018-08-21 2018-08-21
Psychopharmacology of Psilocybin in Cancer Patients NCT00465595 Depressive Symptoms · Anxiety · Cancer	Johns Hopkins University PHASE2	Completed Registry updated 2018-07-19	56 ACTUAL	2007-04 2014-12 2016-12
Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior NCT00802282 Healthy	Johns Hopkins University PHASE1	Completed Registry updated 2016-02-24	75 ACTUAL	2009-08 2014-02 2014-05
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators NCT01988311 Psilocybin · Hallucinogens · Pharmacologic Actions · Central Nervous System Agents · Therapeutic Uses · Psychotropic Drugs	Johns Hopkins University PHASE1	Completed Registry updated 2014-05-20	10 ESTIMATED	2013-05 2014-01 2014-05

Reported research facilities

Brown University School of Public HealthProvidence, Rhode Island, United States

National Institute of Aging, Clinical Research UnitBaltimore, Maryland, United States

FLMiami, Florida, United States

FLOrlando, Florida, United States

ILChicago, Illinois, United States

MNEden Prairie, Minnesota, United States

NELincoln, Nebraska, United States

NVLas Vegas, Nevada, United States

NYNew York, New York, United States

BCNorth Vancouver, British Columbia, Canada

MD Anderson Cancer CenterHouston, Texas, United States

Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States

Emory University HospitalAtlanta, Georgia, United States

University of WisconsinMadison, Wisconsin, United States

Yale UniversityNew Haven, Connecticut, United States

Olin Neuropsychiatry Research CenterHartford, Connecticut, United States

Brigham and Women's HospitalBoston, Massachusetts, United States

Oregon Health & Science UniversityPortland, Oregon, United States

M Health Fairview DBT ProgramMinneapolis, Minnesota, United States

M Physicians St. Louis Park ClinicSaint Louis Park, Minnesota, United States

University of Alabama at BirminghamBirmingham, Alabama, United States

University of California San Francisco (UCSF) Department of NeurologySan Francisco, California, United States

University of Colorado Anschutz Medical CampusAurora, Colorado, United States

Emory University Brain Health CenterAtlanta, Georgia, United States

Dana-Farber Cancer InstituteBoston, Massachusetts, United States

University of Nebraska Medical CenterOmaha, Nebraska, United States

New York University Langone Health, Center for Psychedelic MedicineNew York, New York, United States

Center for Psychedelics and Consciousness Research in the Behavioral Biology Research CenterBaltimore, Maryland, United States

NYU Langone HealthNew York, New York, United States

Center for Psychedelics and Consciousness ResearchBaltimore, Maryland, United States

University of California San Francisco, Sandler Neuroscience BuildingSan Francisco, California, United States

Johns Hopkins University School of MedicineBaltimore, Maryland, United States

Outpatient CTRCAurora, Colorado, United States

University of Colorado Cancer CenterAurora, Colorado, United States

University of California, San FranciscoSan Francisco, California, United States

UC San DiegoSan Diego, California, United States

Connecticut Mental Health CenterNew Haven, Connecticut, United States

Vail Health Behavioral HealthEdwards, Colorado, United States

5510 Nathan Shock DriveBaltimore, Maryland, United States

Birmingham VA Medical Center, Birmingham, ALBirmingham, Alabama, United States

Tuscaloosa VA Medical Center, Tuscaloosa, ALTuscaloosa, Alabama, United States

VA Portland Health Care System, Portland, ORPortland, Oregon, United States

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PAPhiladelphia, Pennsylvania, United States

VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, Washington, United States

UW School of Medicine and Public HealthMadison, Wisconsin, United States

The Parsons Research Center for Psychedelic HealingNew York, New York, United States

Athinoula A. Martinos Center for Biomedical ImagingCharlestown, Massachusetts, United States

University of Washington Center for Novel Therapeutics in Addiction PsychiatrySeattle, Washington, United States

The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States

The University of Texas Health Science Center at HoustonHouston, Texas, United States

Roswell Park Cancer InstituteBuffalo, New York, United States

UCSF at Zuckerberg San Francisco General HospitalSan Francisco, California, United States

Lighthouse Psychiatry ScottsdaleGilbert, Arizona, United States

Clinical Innovations, Inc.Bellflower, California, United States

M3 Wake ResearchEncino, California, United States

The Regents of the University of California - San DiegoLa Jolla, California, United States

Kadima Neuropsychiatry InstituteLa Jolla, California, United States

CalNeuro Research Group, IncLos Angeles, California, United States

Catalina Research Institute, LLCMontclair, California, United States

Piedmont Hospital Neuroscience CentreOakland, California, United States

ATP Clinical Research, Inc.Orange, California, United States

CITrialsRiverside, California, United States

Lumos Clinical Research CenterSan Jose, California, United States

Syrentis Clinical ResearchSanta Ana, California, United States

Stanford UniversityStanford, California, United States

ASCLEPES Research CentersThousand Oaks, California, United States

Pacific Clinical Research Management Group, LLCUpland, California, United States

Innovative Clinical Research, Inc.Lauderhill, Florida, United States

Central Miami Medical Institute, LLCMiami, Florida, United States

Behavioral Clinical Research, Inc.Miami Lakes, Florida, United States

Health Synergy Clinical ResearchOkeechobee, Florida, United States

Clinical Neurosciecne Solutions, Inc. dba CNS HealthcareOrlando, Florida, United States

APG Research, LLC- Advanced Psychiatric GroupOrlando, Florida, United States

University South FloridaTampa, Florida, United States

Stedman Clinical TrialsTampa, Florida, United States

Health Synergy Clinical Research, LLCWest Palm Beach, Florida, United States

Atlanta Center for Medical ResearchAtlanta, Georgia, United States

iResearch AtlantaDecatur, Georgia, United States

Rush University Medical CenterChicago, Illinois, United States

Uptown Research Institute, LLCChicago, Illinois, United States

Psychiatric Medicine AssociatesSkokie, Illinois, United States

Harvard Medical School - McLean HospitalBelmont, Massachusetts, United States

Adams Clinical - Boston (Copley Clinical)Boston, Massachusetts, United States

University of Massachusetts Medical SchoolNorth Worcester, Massachusetts, United States

Adams Clinical - BostonWatertown, Massachusetts, United States

Michigan Clinical Research Institute PCAnn Arbor, Michigan, United States

University Of Michigan Comprehensive Depression CenterAnn Arbor, Michigan, United States

Institute for Integrative TherapiesEden Prairie, Minnesota, United States

St. Charles Psychiatric Associates - Midwest Research GroupSaint Charles, Missouri, United States

Alivation Research, LLC.Lincoln, Nebraska, United States

Hassman Research InstituteBerlin, New Jersey, United States

Princeton Medical InstitutePrinceton, New Jersey, United States

Bio Behavioral HealthToms River, New Jersey, United States

Dent Neurosciences Research Center, Inc.Amherst, New York, United States

Fieve Clinical Research, IncNew York, New York, United States

Spectrum Neuroscience and Treatment InstituteNew York, New York, United States

Adams Clinical - New YorkNew York, New York, United States

New York State Psychiatric InstituteNew York, New York, United States

Richmond Behavioral AssociatesStaten Island, New York, United States

Adams Clinical - New YorkThe Bronx, New York, United States

University of Cincinnati, Department of Psychiatry & Behavirol NeuroscienceCincinnati, Ohio, United States

Cleveland Clinic - Lutheran HospitalCleveland, Ohio, United States

The Ohio State UniversityColumbus, Ohio, United States

Suburban Research AssociatesMedia, Pennsylvania, United States

The University of Texas at Austin - Dell Medical SchoolAustin, Texas, United States

Houston Clinical Trials, LLCBellaire, Texas, United States

Relaro Medical TrialsDallas, Texas, United States

Center for Depression Research and Clinical CareDallas, Texas, United States

North Texas Clinical TrialsFort Worth, Texas, United States

Brain Health Consultants and TMS CenterHouston, Texas, United States

HCA Healthcare Research Institute - Medical City Green Oaks HospitalPlano, Texas, United States

Cedar Clinical ResearchDraper, Utah, United States

The University of Utah - Huntsman Mental Health InstituteSalt Lake City, Utah, United States

Seattle Neuropsychiatric Treatment CenterSeattle, Washington, United States

Diex Recherche Sherbrooke Inc.Québec, B.C., Canada

Medical Arts Health Research Centre, KamloopsKamloops, British Columbia, Canada

Okanagan Clinical TrialsKelowna, British Columbia, Canada

Medical Arts Research Group - PentictonPenticton, British Columbia, Canada

Chatham-Kent Clnical Trials CentreChatham, Ontario, Canada

St. Michael's HospitalToronto, Ontario, Canada

Centre for Addiction and Mental Health (CAMH)Toronto, Ontario, Canada

Centre for Neurology StudiesVancouver, Canada

Medical Arts Research GroupVancouver, Canada

National Institute of Mental HealthKlecany, Czechia

Neuroterapie KH SroKutná Hora, Czechia

Psychiatric AmbulanceOstrava, Czechia

A-Shine s.r.o.Pilsen, Czechia

Psychedelicka klinika, s.r.o.Prague, Czechia

Institut Neuropsychiatricke PecePrague, Czechia

Aalborg Universitetshospital-Psykiatrien Region NordjyllandAalborg, Denmark

Ghu-Centre Hospitalier Sainte Anne, Centre de Recherche CliniqueParis, Paris, France

Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire CaremeauNîmes, France

Universite Paris VI Pierre et Marie Curie - Hopital de La Salpetriere - Centre Emotion - USR 3246 (CNRS UMR 7593)Paris, France

Centre Hospitalier Sainte Anne - Clinique des Maladies Mentales et de l'Encephale (CMME)Paris, France

Charite-Universitaetsmedizin BerlinBerlin, Germany

Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Psychiatrie, Psychosomatik und PsychotherapieFrankfurt, Germany

ZiP Campus LuebeckLübeck, Germany

Tallaght University HospitalDublin, Ireland

La Nua Day Hospital Mental Health CentreGalway, Ireland

University Medical Center GroningenGroningen, Netherlands

Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center) - Leiden Institute for Brain and Cognition (LIBC)Leiden, Netherlands

Universitair Medisch Centrum Utrecht (UMC Utrecht)Utrecht, Netherlands

Promente - Ośrodek Badań KlinicznychBydgoszcz, Poland

Uniwersyteckle Centrum Kliniczne, Klinika Psychiatrii DoroslychGdansk, Poland

Centrum Badan Klinicznych PI-House Sp. z o.o.Gdansk, Poland

Hospital Clinic de BarcelonaBarcelona, Spain

Parc Sanitari Sant Joan de Deu (Sant Joan de Deu Serveis de Salut Mental)Barcelona, Spain

Hospital Universitario Fundacion Jimenez DiazMadrid, Spain

FIDMAG Hermanas HospitalariasSant Boi de Llobregat, Spain

Hospital Universitario Río Hortega de ValladolidValladolid, Spain

Hospital Provincial de Zamora - Servicio de PsiquiatriaZamora, Spain

VuxenpsykiatrimottagningenLandskrona, Sweden

Lunds Universitet - Medicinska Fakulteten (Lund University Faculty of Medicine)Lund, Sweden

ClinSmart Sweden ABSolna, Sweden

HälsoklustretStockholm, Sweden

Cornwall Partnership NHS Foundation TrustBodmin, Cornwall, United Kingdom

Abraham Cowley Unit - Surrey and Borders Partnership NHS Foundation TrustChertsey, United Kingdom

St. Pancras Clinical ResearchChester, United Kingdom

Grounded Research Hub - Rotherham Doncaster & South Humber NHS Foundation TrustDoncaster, United Kingdom

Clinical Research Facility, Royal Devon and Exeter HospitalExeter, United Kingdom

Fulbourn Hospital - Cambridgeshire And Peterborough NHS Foundation TrustFulbourn, United Kingdom

St. Pancras Clinical ResearchLondon, United Kingdom

King's College London - Institute of Psychiatry, PsychologyLondon, United Kingdom

Clerkenwell HealthLondon, United Kingdom

Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust - Wolfson Research CentreNewcastle, United Kingdom

University Of Nottingham/Nottinghamshire Healthcare Trust, Institute Of Mental HealthNottingham, United Kingdom

The Warneford Hospital- NIHR Clinical Research FacilityOxford, United Kingdom

Sheffield Health and Social Care NHS Foundation TrustSheffield, United Kingdom

James J. Peters Department of Veterans Affairs Medical CenterThe Bronx, New York, United States

ProScience Research GroupCulver City, California, United States

Collaborative Neuroscience Network, LLCGarden Grove, California, United States

University California San DiegoLa Jolla, California, United States

California Center for Psychedelic TherapyLos Angeles, California, United States

Clarity Clinical Research, LLCLos Angeles, California, United States

Artemis Institute for Clinical ResearchSan Diego, California, United States

Comprehensive Psychiatric CareNorwich, Connecticut, United States

APG Research, LLCOrlando, Florida, United States

DMI Health Care Group, IncTampa, Florida, United States

Meridien Research/Accel ResearchTampa, Florida, United States

Psych AtlantaAtlanta, Georgia, United States

Emory UniversityAtlanta, Georgia, United States

Sheppard Pratt Health SystemBaltimore, Maryland, United States

CBH Health, LLCGaithersburg, Maryland, United States

Pharmasite Research, IncPikesville, Maryland, United States

University of MinnesotaMinneapolis, Minnesota, United States

University of MissouriColumbia, Missouri, United States

Midwest Research GroupSaint Charles, Missouri, United States

Washington University School of MedicineSt Louis, Missouri, United States

The Medical Research Network, LLCNew York, New York, United States

Insight Clinical Trials, LLCBeachwood, Ohio, United States

Neuro-Behaviroral Clinical Research, Inc.North Canton, Ohio, United States

Rivus Wellness & Research InstituteOklahoma City, Oklahoma, United States

Global Medical Institutes, LLC, Scranton Medical InstituteMoosic, Pennsylvania, United States

UT Health Science Center at Houston (UTHSC-H)Houston, Texas, United States

Core Clinical ResearchEverett, Washington, United States

Johns Hopkins School of MedicineBaltimore, Maryland, United States

UPMC PresbyterianPittsburgh, Pennsylvania, United States

Univeristy of Southern California Brain and Creativity InstituteLos Angeles, California, United States

Department of Veterans AffairsWest Haven, Connecticut, United States

Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States

Scottsdale Research InstituteScottsdale, Arizona, United States

University of Wisconsin - MadisonMadison, Wisconsin, United States

The Clinical and Translational Sciences Research CenterTucson, Arizona, United States

University of Alabama Clinical Research UnitBirmingham, Alabama, United States

Preferred Research Partners-NWA, LLCFayetteville, Arkansas, United States

Preferred Research Partners, Inc.Little Rock, Arkansas, United States

West LA VA Medical Center - Mental Health DepartmentLos Angeles, California, United States

Pacific Neuroscience Institute (PNI) at Saint John's Physician PartnersSanta Monica, California, United States

Psychedelic Science InstituteSanta Monica, California, United States

Mountain View Clinical ResearchDenver, Colorado, United States

Connecticut Mental Health Center, Yale UniversityNew Haven, Connecticut, United States

Clinical Neuroscience Solutions Inc.Jacksonville, Florida, United States

Clinical Neuroscience Solutions, Inc.Orlando, Florida, United States

CenExel iResearch, LLCDecatur, Georgia, United States

Great Lakes Clinical TrialsChicago, Illinois, United States

Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States

Sunstone Medical PCRockville, Maryland, United States

VA Nebraska Western Iowa Health Care SystemOmaha, Nebraska, United States

Global Medical Institutes, LLC; Princeton Medical InstitutePrinceton, New Jersey, United States

University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) CenterAlbuquerque, New Mexico, United States

NYU Clinical & Translational Science InstituteNew York, New York, United States

Bronx Veterans Research Foundation at the James J. Peters VAMCThe Bronx, New York, United States

AIM Trials, LLCPlano, Texas, United States

Clinical Trials of Texas, LLCSan Antonio, Texas, United States

Cedar Clinical Research, Inc.Murray, Utah, United States

Seattle Neuropsychiatric Treatment CenterBellevue, Washington, United States

VA Portland Health Care SystemVancouver, Washington, United States

The Ohio State University Department of PsychiatryColumbus, Ohio, United States

VA Connecticut Healthcare SystemWest Haven, Connecticut, United States

University of California, BerkeleyBerkeley, California, United States

Connecticut Mental Health CenterHamden, Connecticut, United States

West Haven VA Medical CenterWest Haven, Connecticut, United States

University of PennsylvaniaPhiladelphia, Pennsylvania, United States

Sunstone Medical, PCRockville, Maryland, United States

New York UniversityNew York, New York, United States

The Ohio State University Medical CenterColumbus, Ohio, United States

University of VirginiaCharlottesville, Virginia, United States

The University of Texas at Austin Dell Medical SchoolAustin, Texas, United States

Enact Research Collaborative (40 Temple St, 4th Floor)New Haven, Connecticut, United States

Yale Program for Psychedelic ResearchNew Haven, Connecticut, United States

UCSF Mission BaySan Francisco, California, United States

Interdisciplinary Substance Use and Brain Injury (ISUBI)Albuquerque, New Mexico, United States

UCLA Semel InstituteLos Angeles, California, United States

UAB Outpatient Clinical Research UnitBirmingham, Alabama, United States

Ohio State University Comprehensive Cancer CenterColumbus, Ohio, United States

University of Arizona-TucsonTucson, Arizona, United States

UNC Chapel Hill Medical CenterChapel Hill, North Carolina, United States

Innovative Clinical Research, Inc. (formerly Segal Trials)Lauderhill, Florida, United States

University of California San FranciscoSan Francisco, California, United States

Portland VA Health Care SystemVancouver, Washington, United States

Pacific Neuroscience InstituteSanta Monica, California, United States

Segal TrialsLauderhill, Florida, United States

Johns Hopkins UniversityBaltimore, Maryland, United States

New York University School of MedicineNew York, New York, United States

University of California, Los AngelesLos Angeles, California, United States

Goodman Hall, Dept of Psychiatry, Indiana UniversityIndianapolis, Indiana, United States

The Stark Neuroscience Building (Goodman Hall)Indianapolis, Indiana, United States

UAB Beacon TowerBirmingham, Alabama, United States

Connecticut Mental Health Center - Yale School of MedicineNew Haven, Connecticut, United States

Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research CenterColumbus, Ohio, United States

Care DimensionsDanvers, Massachusetts, United States

Johns HopkinsBaltimore, Maryland, United States

Massachusetts General HospitalBoston, Massachusetts, United States

Duke City Recovery ToolboxAlbuquerque, New Mexico, United States

University of New MexicoAlbuquerque, New Mexico, United States

StartCareBrooklyn, New York, United States

VIP Community Services, IncThe Bronx, New York, United States

Baylor College of MedicineHouston, Texas, United States

University of California, San DiegoSan Diego, California, United States

University of ChicagoChicago, Illinois, United States

University of Colorado Anschutz Medical campus (CU AMC)Aurora, Colorado, United States

University of Iowa Health CareIowa City, Iowa, United States

Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600Austin, Texas, United States

Marin Cancer CareGreenbrae, California, United States

University of San FranciscoSan Francisco, California, United States

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, California, United States

Sunstone TherapiesRockville, Maryland, United States

University of IowaIowa City, Iowa, United States

VA Connecticut Healthcare System, West Haven CampusWest Haven, Connecticut, United States

Washington UniversitySt Louis, Missouri, United States

LSU Health ShreveportShreveport, Louisiana, United States

Innertrek Patient Service CenterPortland, Oregon, United States

Behavioral Pharmacology Research UnitBaltimore, Maryland, United States

Clinical Neuroscience Solutions IncJacksonville, Florida, United States

Elixia MA, LLCSpringfield, Massachusetts, United States

Aims TrialPlano, Texas, United States

Emory University/Winship Cancer InstituteAtlanta, Georgia, United States

Brain Health Center at Executive ParkAtlanta, Georgia, United States

Icahn School of Medicine at Mount SinaiNew York, New York, United States

Kings College London, Institute of Psychiatry, Psychology and NeurologyLondon, United Kingdom

National University of Natural MedicinePortland, Oregon, United States

Neuroimaging Research Branch, NIDA-IRPBaltimore, Maryland, United States

University of Wisconsin Hospital and ClinicsMadison, Wisconsin, United States

Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy ResearchNew York, New York, United States

Chronic Pain and Fatigue Research CenterAnn Arbor, Michigan, United States

University of WashingtonSeattle, Washington, United States

Harbor-UCLA Medical CenterTorrance, California, United States

Altman Clinical and Translational Research InstituteSan Diego, California, United States

Dell Medical SchoolAustin, Texas, United States

University of FloridaGainesville, Florida, United States

Huntsman Mental Health InstituteSalt Lake City, Utah, United States

University of ArizonaTucson, Arizona, United States

VA Palo Alto Healthcare System/Stanford MedicinePalo Alto, California, United States

Behavioral Biology Research Center, Johns Hopkins BayviewBaltimore, Maryland, United States

Huntsman Cancer InstituteSalt Lake City, Utah, United States

Mount Sinai Comprehensive Cancer CenterMiami Beach, Florida, United States

Sheaf House, Tallaght HospitalDublin, Ireland

University of New Mexico Health Sciences CenterAlbuquerque, New Mexico, United States

Altasciences Clinical Kansas, IncOverland Park, Kansas, United States

UWHealth, 600 Highland AvenueMadison, Wisconsin, United States

Altman Clinical and Translational Research Institute, University of CaliforniaSan Diego, California, United States

Stanford Department of PsychiatryStanford, California, United States

Mood and Anxiety Disorders Program Emory University School of MedicineAtlanta, Georgia, United States

Ray Worthy Psychiatry LLCNew Orleans, Louisiana, United States

UT Center of Excellence on Mood Disorders, University of Texas Health Science CenterHouston, Texas, United States

Canadian Rapid Treatment Centre of ExcellenceMississauga, Ontario, Canada

Centre for Addiction and Mental HealthToronto, Ontario, Canada

National Institute of Mental Health Czech RepublicKlecany, Czechia

Enhed for Psykiatrisk Forskning, Psykiatrien i AalborgAalborg, Denmark

Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin FranklinBerlin, Germany

Groningen University Medical CentreGroningen, Netherlands

Leiden University Medical CentreLeiden, Netherlands

Utrecht University Medical CentreUtrecht, Netherlands

Unidade de Neuropsiquiatria, Centro Clinico ChampalimaudLisbon, Portugal

Hospital de Dia NumanciaBarcelona, Spain

Institute Hospital del Mar of Medical Research (IMIM)Barcelona, Spain

Clinical Research and Imaging CentreBristol, Avon, United Kingdom

Wolfson Research Centre, Campus for Ageing and VitalityNewcastle upon Tyne, Tyne and Wear, United Kingdom

Greater Manchester Mental Health Foundation TrustManchester, United Kingdom

New York State Psychiatric Institute, 1051 Riverside DriveNew York, New York, United States

Pacific Treatment & Research in PsychedelicsSanta Monica, California, United States

Ross Allison NPI #1437519899 Administrator Of StudyBozeman, Montana, United States

Clinical and Translational Science Institute, NYU Langone Medical CenterNew York, New York, United States

Sheppard PrattBaltimore, Maryland, United States

Altman Clinical and Translational Research InstituteLa Jolla, California, United States

NYU Langone Medical Center/Tisch HospitalNew York, New York, United States

Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical CenterBaltimore, Maryland, United States

Maryland Oncology Hematology PARockville, Maryland, United States

NYU College of Dentistry Bluestone Center for Clinical ResearchNew York, New York, United States

University of Wisconsin, School of PharmacyMadison, Wisconsin, United States

Behavioral Pharmacology Research Unit, Johns Hopkins Bayview CampusBaltimore, Maryland, United States

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.